Xu L C, Nakayama M, Harada K, Kuniyasu A, Nakayama H, Tomiguchi S, Kojima A, Takahashi M, Ono M, Arano Y, Saji H, Yao Z, Sakahara H, Konishi J, Imagawa Y
Faculty of Pharmaceutical Sciences, Kumamoto University, Oe-Honmachi, Japan.
Bioconjug Chem. 1999 Jan-Feb;10(1):9-17. doi: 10.1021/bc980024j.
To develop chelating molecules that provide 99mTc-labeled polypeptides of high in vivo stability and high specific activities under mild reaction conditions, an asymmetrical bis(benzohydroxamamide) compound with an amine group, 4'-aminomethyl-N,N'-trimethylenedibenzohydroxamamide [NH2-C3(BHam)2], was designed and synthesized. The amine residue of NH2-C3(BHam)2 was converted to a maleimide group by reaction with N-succinimidyl-6-maleimidohexanoate, and the conjugation product was coupled to thiol groups of a monoclonal antibody against osteogenic sarcoma (OST7, IgG1) pretreated with 2-iminothiolane to prepare C3(BHam)2-OST7. 99mTc radiolabeling of C3(BHam)2-OST7 was performed by the exchange reaction with [99mTc]glucoheptonate. [99mTc]C3(BHam)2-OST7 was further characterized using directly radioiodinated OST7 ([125I]OST7) and [111In]labeled OST7 with 1-[4-[(5-maleimidopentyl)amidobenzyl]ethylenediamine-N,N, N'N'-tetraacetic acid (EMCS-Bz-EDTA) as references. [99mTc]C3(BHam)2-OST7 was obtained with radiochemical yields of over 94% at protein concentrations as low as 0.2 mg/mL at room temperature for 1 h. [99mTc]C3(BHam)2-OST7 remained stable after incubation in freshly prepared murine plasma and in the presence of cysteine. Similar binding affinities to tumor cells were observed between [99mTc]C3(BHam)2-OST7 and [125I]OST7. When injected into normal mice, [99mTc]C3(BHam)2-OST7 exhibited radioactivity levels in the blood similar to [111In]-EMCS-Bz-EDTA-OST7 up to 24 h postinjection with significantly faster elimination rate of the radioactivity from the liver. In nude mice bearing osteogenic sarcoma, no significant differences were observed in the radioactivity levels in the blood and the tumor between [99mTc]C3(BHam)2-OST7 and [125I]OST7 at 24 h postinjection. These findings indicated that C3(BHam)2 provided 99mTc chelate of high stability at low concentrations even when conjugated to an intact antibody. Such characteristics render bis(hydroxamamide) compounds useful as chelating molecules for preparation of 99mTc-labeled polypeptides.
为了开发在温和反应条件下能提供具有高体内稳定性和高比活度的99mTc标记多肽的螯合分子,设计并合成了一种带有胺基的不对称双(苯甲酰氧肟酸)化合物,即4'-氨甲基-N,N'-三亚甲基二苯甲酰氧肟酸[NH2-C3(BHam)2]。通过与N-琥珀酰亚胺基-6-马来酰亚胺己酸反应,将NH2-C3(BHam)2的胺残基转化为马来酰亚胺基团,然后将共轭产物与用2-亚氨基硫杂环戊烷预处理的抗骨肉瘤单克隆抗体(OST7,IgG1)的巯基偶联,制备C3(BHam)2-OST7。通过与[99mTc]葡庚糖酸盐的交换反应对C3(BHam)2-OST7进行99mTc放射性标记。使用直接放射性碘化的OST7([125I]OST7)和用1-[4-[(5-马来酰亚胺戊基)氨基苄基]乙二胺-N,N,N',N'-四乙酸(EMCS-Bz-EDTA)标记的[111In]OST7作为参考,对[99mTc]C3(BHam)2-OST7进行进一步表征。在室温下1小时,当蛋白质浓度低至0.2mg/mL时,[99mTc]C3(BHam)2-OST7的放射化学产率超过94%。[99mTc]C3(BHam)2-OST7在新鲜制备的小鼠血浆中孵育以及在有半胱氨酸存在的情况下仍保持稳定。观察到[99mTc]C3(BHam)2-OST7与[125I]OST7对肿瘤细胞具有相似的结合亲和力。当注射到正常小鼠体内时,[99mTc]C3(BHam)2-OST7在注射后24小时内血液中的放射性水平与[111In]-EMCS-Bz-EDTA-OST7相似,但其从肝脏中清除放射性的速率明显更快。在荷骨肉瘤的裸鼠中,注射后24小时,[99mTc]C3(BHam)2-OST7与[125I]OST7在血液和肿瘤中的放射性水平没有显著差异。这些发现表明,即使与完整抗体偶联,C3(BHam)2在低浓度下也能提供高稳定性的99mTc螯合物。这些特性使得双(氧肟酸)化合物可作为制备99mTc标记多肽的螯合分子。